FiftyBidsGovernment contracts and grants, sent to your inbox.

Back to search

Open grant

Minor Use Minor Species Development of Drugs (R01)

This Notice of Funding Opportunity (NOFO) is issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), and solicits Research Project (R01) grant applications from institutions or organizations that propose to develop or support the development of designated new animal drugs intended for…

FromFood and Drug Administration
Who can applystate governments, counties, cities and townships, special districts (water, fire, parks, etc.), school districts, public colleges and universities and 9 more types
Eligibility notes• Faith-based or Community-based Organizations• Regional Organizations• Non-domestic (non-U.S.) Entities (Foreign Organizations)
How muchup to $250K per award; $250K total
DeadlineFri, Jan 29, 2027 (98 days left)
CategoryAgriculture, Consumer Protection, Food and Nutrition
TypeGrant
Opportunity #PAR-24-216
Assistance listing93.103
PostedWed, May 29, 2024

Open the official posting

From the notice

This Notice of Funding Opportunity (NOFO) is issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), and solicits Research Project (R01) grant applications from institutions or organizations that propose to develop or support the development of designated new animal drugs intended for minor uses in major species or for use in minor species (MUMS). The FDA is authorized to provide grants to assist in defraying the costs of qualified safety and effectiveness testing that could be used to satisfy the requirements for FDA approval of MUMS-designated drugs. Only entities developing drugs for veterinary use or parties working as research partners with such entities are eligible for grants. The organization (or applicant) seeking approval of the new animal drug under investigation must have opened an Investigational New Animal Drug (INAD) file with FDA/CVM and must hold a minor use or minor species "designation" granted by FDA/CVM's Office of Minor Use and Minor Species Animal Drug Development (OMUMS) for that drug for a specified intended use, in accordance with the provisions of section 573 of the Food, Drug and Cosmetic Act (21 U.S.C. 360ccc-2) and 21 CFR part 516. FDA/CVM's Office of New Animal Drug Evaluation (ONADE) must have reviewed and concurred with the proposed study protocol before an applicant can submit a grant application.

We may have shortened this. The official posting is the record. We are not affiliated with the agency that published it.